Repositori institucional URV
| URV's Author/s: | Folch Lopez, Jaume |
| Author, as appears in the article.: | Sánchez-López E, Ettcheto M, Egea MA, Espina M, Calpena AC, Folch J, Camins A, García ML. |
| Author's mail: | jaume.folch@urv.cat |
| Author identifier: | 0000-0002-5051-8858 |
| Journal publication year: | 2017 |
| Publication Type: | Journal Publications |
| ISSN: | 15499634 |
| APA: | Sánchez-López E, Ettcheto M, Egea MA, Espina M, Calpena AC, Folch J, Camins A, García ML. (2017). New potential strategies for Alzheimer's disease prevention: pegylated biodegradable dexibuprofen nanospheres administration to APPswe/PS1dE9. Nanomedicine-Nanotechnology Biology And Medicine, 13(3), 1171-1182. DOI: 10.1016/j.nano.2016.12.003 |
| Papper original source: | Nanomedicine-Nanotechnology Biology And Medicine. 13 (3): 1171-1182 |
| Abstract: | Dexibuprofen loaded pegylated poly(lactic-co-glycolic) nanospheres prepared by solvent diffusion method were designed to increase Dexibuprofen brain delivery reducing systemic side effects. Nanospheres exhibited a mean particle size around 200 nm (195.4 nm), monomodal population and negative surface charge. Drug loaded nanospheres showed a sustained release profile, allowing to modify the posology in vivo. Nanospheres were non-toxic neither in brain endothelial cells nor astrocytes and do not cause blood¿brain barrier disruption. Nanospheres were able to partially cross the cells barrier and release the drug after co-culture in vitro experiments, increasing Dexibuprofen permeation coefficient. Behavioral tests performed in APPswe/PS1dE9 mice (mice model of familial Alzheimer's disease) showed that nanospheres reduce memory impairment more efficiently than the free drug. Developed nanospheres decrease brain inflammation leading to ¿-amyloid plaques reduction. According to these results, chronical oral Dexibuprofen pegylated poly(lactic-co-glycolic) nanosystems could constitute a suitable strategy for the prevention of neurodegeneration. |
| Article's DOI: | 10.1016/j.nano.2016.12.003 |
| Link to the original source: | https://www.sciencedirect.com/science/article/abs/pii/S1549963416302209?via%3Dihub |
| Papper version: | info:eu-repo/semantics/acceptedVersion |
| licence for use: | https://creativecommons.org/licenses/by/3.0/es/ |
| Department: | Bioquímica i Biotecnologia |
| Licence document URL: | https://repositori.urv.cat/ca/proteccio-de-dades/ |
| Thematic Areas: | Química Psicología Pharmaceutical science Odontología Nanoscience and nanotechnology Nanoscience & nanotechnology Molecular medicine Medicine, research & experimental Medicine (miscellaneous) Medicina veterinaria Medicina iii Medicina ii Medicina i Materials science (miscellaneous) Materials science (all) Materiais Interdisciplinar General medicine General materials science Farmacia Engenharias iv Engenharias iii Engenharias ii Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciências agrárias i Biotecnología Biomedical engineering Bioengineering Astronomia / física |
| Keywords: | Plga-peg Ocular delivery Nanospheres Nanoparticles Mouse model Lipid nanoparticles In-vitro Flurbiprofen Ex-vivo Drug-release Dried plga nanoparticles Dexibuprofen Design Blood–brain barrier Blood-brain-barrier Blood-brain barrier Alzheimer's disease nanospheres nanoparticles dexibuprofen blood–brain barrier alzheimer's disease |
| Entity: | Universitat Rovira i Virgili |
| Record's date: | 2024-09-07 |
| Search your record at: |   |
| File | Description | Format | |
|---|---|---|---|
| DocumentPrincipal | DocumentPrincipal | application/pdf |
© 2011 Universitat Rovira i Virgili